Inactive Instrument

Translate Bio, Inc.

TBIO

US89374L1044

Biotechnology & Medical Research

Translate Bio, Inc.(NasdaqGS:TBIO) dropped from S&P Global BMI Index

September 20, 2021 at 12:00 am EDT

Latest news about Translate Bio, Inc.

Translate Bio, Inc.(NasdaqGS:TBIO) dropped from S&P TMI Index	21-09-20	CI
Translate Bio, Inc.(NasdaqGS:TBIO) dropped from S&P Global BMI Index	21-09-20	CI
Translate Bio, Inc.(NasdaqGS:TBIO) dropped from S&P Biotechnology Select Industry Index	21-09-20	CI
Insider Sell: Translate Bio	21-09-15	MT
Insider Sell: Translate Bio	21-09-15	MT
Insider Sell: Translate Bio	21-09-15	MT
Translate Bio : Sanofi Completes Translate Bio Buyout	21-09-14	MT
Translate Bio, Inc.(NasdaqGS:TBIO) dropped from NASDAQ Composite Index	21-09-14	CI
Translate Bio, Inc.(NasdaqGS:TBIO) dropped from NASDAQ Biotechnology Index	21-09-13	CI
Sanofi completed the acquisition of remaining 95.1% stake in Translate Bio, Inc. from The Baupost Group, LLC, Ronald Renaud and other shareholders.	21-09-12	CI
VC Daily : Laronde Fundraising Haul Reflects -2-	21-09-02	DJ
VC Daily : Laronde Fundraising Haul Reflects Search for Next Moderna	21-09-02	DJ
Translate Bio, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-05	CI
AstraZeneca : Analysis-Sanofi's COVID-19 vaccine setback, drug pipeline cast long shadow	21-08-05	RE
TRANSLATE BIO : Roth Capital Adjusts Translate Bio's Price Target to $38 from $45, Keeps Neutral Rating	21-08-04	MT
Apple : S&P 500 closes at record high as Apple, healthcare stocks help shrug off Delta worries	21-08-03	RE
Top Midday Gainers	21-08-03	MT
TRANSLATE BIO : SVB Leerink Adjusts Translate Bio's Price Target to $38 from $19, Keeps Market Perform Rating	21-08-03	MT
TRANSLATE BIO : Jefferies Downgrades Translate Bio to Hold from Buy	21-08-03	MT
TRANSLATE BIO : William Blair Downgrades Translate Bio to Market Perform From Outperform	21-08-03	MT
Global markets live: Sanofi, Alphabet, BMW, Ford, Tencent...	21-08-03
GlaxoSmithKline : Sanofi bets on mRNA vaccines beyond COVID in $3.2 billion Translate Bio deal	21-08-03	RE
Today on Wall Street: Corporate profits rise by a level not seen since 2009	21-08-03
Sector Update: Health Care Stocks Flat To Higher Pre-Bell Tuesday	21-08-03	MT
DJ Industrial : Wall Street Set for Small Gains, Earnings in Focus	21-08-03	MT

Translate Bio, Inc. is a messenger RNA, or mRNA, therapeutics company. The Company is developing medicines to treat diseases caused by protein or gene dysfunction. The Company is using its proprietary mRNA therapeutic platform, or MRT platform, and it create mRNA that encodes functional proteins. The mRNA is delivered to the target cell where the cell's own machinery recognizes it and translates it, restoring or augmenting protein function to treat or prevent disease. The MRT product candidate for the lung, MRT5005, is designed to address the underlying cause of CF by delivering mRNA encoding fully functional CFTR protein to the lung epithelial cells through nebulization.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.18%	104B
REGENERON PHARMACEUTICALS, INC.	+1.74%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.86%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-17.69%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+3.94%	13.98B
SAREPTA THERAPEUTICS, INC.	+33.29%	11.66B

Bio Therapeutic Drugs